Celcuity Q2 Loss Widens to $78.9M as Launch Spending Ramps; Cash Runway to 2029

summarizeSummary

Celcuity reported a wider Q2 net loss of $78.9M on higher launch spending, with $754M in cash providing runway into 2029. The company highlighted NCCN Category 1 status for REVTORPYK and positive PIK3CA mutant data ahead of a Q3 sNDA submission.

check_boxKey Events · Earnings and Guidance · CELC

• Q2 Net Loss Widens on Launch Spending

  Net loss was $78.9M ($1.44/share) vs $45.3M ($1.04/share) a year ago, driven by a $27.4M increase in SG&A to $35.0M, of which $23.4M related to commercial headcount and launch activities.

• Cash Runway Extended to 2029

  Cash, cash equivalents and short-term investments totaled $754.0M at June 30, 2026, which management expects will fund operations at least into 2029.

• NCCN Category 1 Recommendation

  REVTORPYK in combination with fulvestrant, with or without palbociclib, received a preferred Category 1 recommendation for second-line HR+/HER2- advanced breast cancer.

• PIK3CA Mutant Cohort Positive; sNDA Planned

  VIKTORIA-1 PIK3CA mutant cohort met its primary endpoint (HR=0.50, p<0.0001); Celcuity plans to submit an sNDA to the FDA in Q3 2026.

auto_awesomeAnalysis · CELC · Industrial Applications And Services

Celcuity's second-quarter loss widened to $78.9 million from $45.3 million a year earlier, driven by a $27.4 million surge in SG&A as the company built out its commercial infrastructure for REVTORPYK. The company holds $754 million in cash and investments, enough to fund operations into 2029, and reiterated a late-Q3 commercial launch timeline. The NCCN Category 1 recommendation and positive PIK3CA mutant cohort data strengthen the launch narrative, but the near-term focus is on execution and the planned sNDA submission in Q3.